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Abstract 
Aim  
To evaluate the reliability and performance of the Xprecia Stride coagulometer under the 
conditions which the coagulometer is most likely be utilised.  
Methods 
The performance of the Xprecia Stride coagulometer was compared with a local laboratory 
and the CoaguChek systems routinely used for INR estimation within one primary and one 
secondary care based anticoagulation clinic in Birmingham. Anticoagulation clinic personnel 
were trained to use the Xprecia Stride. Patients attending the clinics were eligible if aged 18 
years or more and had received warfarin for at least 3 months. Consenting participants 
provided capillary blood samples for parallel testing on the Xprecia Stride and CoaguChek 
systems. At the secondary care clinic, a venous blood sample was also collected for 
laboratory INR estimation. INR results were compared using linear regression analysis and 
Bland Altman plots. 
Results 
A total of 102 laboratory and 205 parallel coagulometer INR tests were performed. Linear 
regression revealed strong correlation between the Xprecia Stride and the laboratory 
(r=0.83) and between the Xprecia Stride and CoaguChek systems (r=0.92). Within the 
therapeutic range agreement between the systems was very good with 87% of the Xprecia 
Stride and laboratory INR results and 93% of the Xprecia Stride and CoaguChek INR results 
being within 0.5 INR units of each other.  
Conclusion  
INRs tested using the Xprecia Stride system showed good agreement with the laboratory 
and CoaguChek systems. Findings indicate that in the hands of the intended users the 
Xprecia Stride is accurate, reliable and acceptable for use in a routine clinical setting. 
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Introduction 
Community management of anticoagulation has increased due to expanding indications for 
warfarin therapy, particularly non rheumatic atrial fibrillation [1] and the introduction of 
reliable point of care (POC) devices for INR estimation. [2-6]  POC devices are defined as 
portable coagulometers designed for use in close proximity to the patient, i.e. at the bedside or 
in the clinic, and are ideal for utilisation outside the laboratory within the community setting. 
Previous primary care based studies comparing INR estimation using POC testing systems 
appropriate for primary care with regional reference laboratories have showed consistency of 
results between systems. [7] Portable coagulometers have also been evaluated widely for 
use in patient self monitoring of warfarin therapy. [8-12]. 
The 2008 Centre for Evidence based Purchasing (CEP) guidelines recommend a number of 
technical, operational and economic considerations for POC devices monitoring oral 
anticoagulation and the British Committee for Standards in Haematology (BCSH) guidelines 
for POC testing also provide recommendations in terms of management, training, equipment 
selection and safety. [13, 14] The CEP guidelines provide a framework for the management 
of POC testing services and the guidance applies to both hospital and community services. 
The guidelines state that devices should have received a successful independent 
performance evaluation and that POC devices should generate results that are comparable 
to those of the local laboratory. An accredited External Quality Assessment (EQA) 
programme and Internal Quality Control (IQC) system must also be in place.  They also state 
that anyone outside the laboratory setting undertaking POC testing should have training and 
annual competency assessment.  The BCSH guidelines recommend an evaluation under the 
conditions most likely to be encountered in normal everyday use i.e. within the community and 
under less highly controlled conditions as seen in the laboratory. 
The Xprecia Stride system is a new to market, Conformité Européenne (CE) marked, point 
of care coagulometer intended for use by healthcare professionals for the monitoring of 
warfarin therapy. It is a hand-held analyzer using a single-use test strip and electrochemical 
technology to measure the prothrombin time in capillary blood samples. Although 
independent Medicines and Healthcare products Regulatory Agency (MHRA) evaluation is no 
longer available, the manufacturers of the Xprecia Stride were keen to seek independent 
evaluation and expert review. (Table 1). The purpose of the current study was therefore to 
evaluate the reliability and performance of the Xprecia Stride under the conditions which the 
coagulometer is most likely be utilised. The primary objective was to determine the level of 
agreement of the INR results obtained using the Xprecia Stride with INR results obtained 
from a local laboratory system and a POC system routinely used in a primary and secondary 
care based anticoagulation clinic.  
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Methods  
The evaluation was conducted over a period of 10 weeks during February and April 2016 in 
one primary care and one secondary care based anticoagulation clinic in Birmingham. The 
anticoagulation clinic personnel were all experienced in the use of POC devices for INR 
estimation. Eight clinic personnel were involved in the evaluation at the secondary care site 
and two at the primary care site. All clinic personnel received training in the evaluation 
protocol from members of the research team. Training in the use of the Xprecia Stride was 
provided by the POC Product Manager, Siemens Healthcare Limited who also supplied the 
clinics with two Xprecia Stride testing systems, test strips (batch number 400570) and 
Internal Quality Control (IQC) materials (batch number 509010). Training reflected the 
training usually given to intended users. Personnel from Siemens Healthcare Ltd were not 
involved in the conduct of the evaluation. Patients attending the anticoagulation clinics were 
eligible to participate if aged 18 years or more and had been receiving warfarin for at least 3 
months. Patients were ineligible if they were housebound or pregnant. Patients registered at 
the primary care anticoagulation clinic received an invitation letter and participant information 
sheet through the post. Patients registered with the secondary care clinic were provided with 
a participant information sheet and invitation to participate when they attended their clinic. 
Eligibility was confirmed by a member of the research team and eligible patients provided 
written informed consent to participate. In the primary care setting, participants consented to 
collection of two samples of capillary blood using one finger stick. In the secondary care 
setting, participants consented to collection of two samples of capillary blood using one 
finger stick and a venous blood sample.  
To meet the minimum requirements of verification of system accuracy, the protocol aimed to 
collect 100 samples at each site to obtain a spread of INR values throughout (i.e. 1.5-4.0) and 
above the therapeutic range (i.e. >4.1). It was not possible to obtain 100 samples at the 
primary care site due to a lower than anticipated attendance at the clinic. To enable 
collection of 200 capillary samples recruitment at the secondary care site continued until 100 
venous and 200 capillary samples with INR results above 1.5 had been collected.  
 
POC testing procedure 
Capillary samples were obtained using the single-use lancing device routinely used in the 
clinic (Accu-Chek Safe-T-Pro Plus, Roche, Mannheim, Germany). POC testing was 
undertaken in parallel on the Xprecia stride system and the routinely used POC system 
using one finger stick and two drops of capillary blood.  The capillary blood sample was 
applied to the two POC devices within 15 seconds of the finger stick being undertaken. The 
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order of the application of the capillary blood to the two machines was varied to ensure an 
equal distribution of samples across the two machines throughout the evaluation period. The 
order of blood application was dictated by the INR case report forms administered to the 
clinic personnel by the research team. In the event that either device failed to display an INR 
result, the finger stick procedure was repeated using a different finger/site if the patient was 
agreeable. The procedure was limited to two attempts so as not to overburden the patient. A 
third finger stick to obtain an INR reading on the routinely used POC device was allowed if 
necessary.  Ethical approval was obtained from the West Midlands Black Country Research 
Ethics Committee Ref 15/WM/0382. Warfarin dose and recall for INR monitoring was based 
upon the INR result obtained on the routinely used POC system.  
The POC device used within the primary care anticoagulation clinic was the CoaguChek XS 
Plus (Roche, Mannheim, Germany), the secondary care clinic used the CoaguChek XS Pro 
(Roche, Mannheim, Germany). The CoaguChek XS Pro has the additional ability to scan bar 
coded patient identification numbers and to connect a data management system through a 
handheld base unit. These CoaguChek systems are otherwise similar, utilising the same test 
materials (CoaguChek XS PT test, Roche) and principle of clot detection. Equivalence 
between INR results determined using these two systems has been previously 
demonstrated. [15]. Four batches of CoaguChek XS PT test strips were utilised at the 
secondary care site (batch numbers 294-030-11, 206-631-11, 206-632-12, and 206-465-12) 
and three batches at the primary care site (batch numbers 294-030-11, 203-359-11 and 205-
138-11). 
 
Venous testing procedure  
At the secondary care site a 4 ml venous blood sample was taken immediately after the POC 
measurements in a siliconised glass citrated anticoagulated sample bottle (containing 0.109 
molars of citrate, Vacutainer system). Tubes were inverted to ensure adequate mixing and 
kept at room temperature until being transported to the hospital laboratory. The laboratory 
system used was the ACL TOP 700, which uses the RecombiPlasTin reagent and routinely 
undergoes INR calibration for each new batch of reagent. The mean normal PT used for the 
laboratory INR calculation was derived from measurement of PT in 20 healthy, non-
anticoagulated patients. A program of daily internal quality assurance using commercial and 
local plasmas is utilized. The laboratory is CPA (Clinical Pathology Accreditation) registered 
and regularly participates in UKNEQAS (UK National External Quality Assurance Service). 
The laboratory performs well within the UKNEQAS blood coagulation EQA scheme achieving 
results which are within consensus. INR measurement was undertaken within 6 hours of 
sample collection.  
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Internal Quality Control 
Internal Quality Control (IQC) procedures were performed on each of the POC systems at 
the start of each clinic. IQC materials were supplied by the manufacturers with one level of 
IQC being performed on the CoaguChek systems and two levels of IQC being performed on 
the Xprecia Stride system in accordance with the instructions for use.  
 
Data collection  
Clinic personnel recorded the INR results obtained in parallel, strip batch numbers and 
details of error messages or repeated attempts on the INR case report form. All IQC results 
were recorded on the IQC case report forms. Technical issues encountered outside of INR 
testing were also recorded.  
 
Analysis  
Scatterplots and linear regression analysis were used to visually explore and assess the 
strength of the linear association between the INR measurements recorded by different 
methods. Agreement between the different methods was then formally assessed via Bland-
Altman plots.  The difference in INR was plotted against the mean INR along with the 
corresponding limits of agreement (mean ± 1.96 SD). The 95% confidence intervals of these 
limits were also displayed.  The pre-defined clinically acceptable limits of agreement were ± 
0.5 INR units. The percentage of samples with bias that occurred outside of these limits is 
reported with corresponding 95% confidence intervals. INR measurements were also 
classified into those ‘in range’ (i.e INR 2-4) and those ‘out of range’. To assess the impact of 
setting, the rate of disagreement in classification of the INR (i.e. in range versus out of 
range) between the Xprecia Stride and CoaguChek systems used within the primary and 
secondary care settings was compared using binomial exact tests.  
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Results  
Samples  
Overall 205 blood samples were collected, 83 in primary care and 122 in the secondary care 
setting. A total of 102 venous blood samples were collected for laboratory INR estimation 
and 205 capillary blood tests were used in parallel for INR estimation on the Xprecia Stride 
and CoaguChek systems. INR results determined by the CoaguChek ranged from 1.3-6.5. 
INR results obtained on the Xprecia Stride ranged from 1.3->8.0. Laboratory determined 
INRs ranged from 1.5-6.6. 
 
INR comparison  
Xprecia Stride versus the Laboratory system 
Regression analysis yielded an intercept of 0.03 units (95% CI -0.39 to 0.45, p=0.89) and a 
slope of 0.98 (95% CI 0.85 to 1.11, p<0.001). The correlation (r) between the Stride and 
laboratory INR testing systems was 0.83 (p<0.001) with R2 of 69%. (Figure 1). These figures 
were obtained from the linear regression and include the outliers. Outliers were identified 
from visual inspection of the scattergrams. Following removal of outliers the correlation (r) 
between the Stride and laboratory INR testing system was 0.97 with R2 94%.  
The Bland-Altman difference plots of the Xprecia Stride and laboratory data revealed a mean 
difference (average bias) of -0.035 units with 95% limits of agreement between -1.46 to 1.40 
and the percent of samples outside ±0.5 bias (within the INR range 1.5 to 4.0) of 12.8% 
(11/86, 95% CI 6.6% to 21.7%). (Figure 2) Following removal of 6 outliers (4 with laboratory 
results outside of the therapeutic range i.e <1.5 and >4.0), the mean bias was 
 -0.14 units with 95% limits of agreement between -0.69 to 0.41 and the percent of samples 
outside ±0.5 bias within the INR range 1.5 to 4.0 of 10.7% (9/84, 95% CI 5.0% to 19.4%).  
 
Xprecia Stride versus the CoaguChek POC systems 
Regression analysis yielded an intercept of units -0.20 (95% CI -0.38 to -0.02, p=0.028) and 
a slope of 1.04 (95% CI 0.98 to 1.10 p<0.001). (Figure 3) The correlation between the Stride 
and CoaguChek INR testing systems was 0.92 with R2 of 85%. Following removal of outliers 
the correlation (r) between the Stride and the CoaguChek systems was 0.94 with R2 89%.  
The Bland-Altman difference plots for the Xprecia Stride and CoaguChek systems revealed 
a mean difference (average bias) of -0.09 units with 95% limits of agreement between -0.95 
to 0.77 and a 6.6 (12/183, 95% CI 3.4 to 11.2%) percent of samples outside ±0.5 bias within 
the INR range 1.5 to 4.0. Following removal of 2 outliers (1 with a CoaguChek result outside 
of the therapeutic range i.e <1.5 and >4.0), the mean bias was -0.12 units with 95% limits of 
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agreement between -0.81 to 0.57 and a percent of samples outside ±0.5 bias within the INR 
range 1.5 to 4.0 of 6.0% (11/182, 95% CI 3.1% to 10.6%).  
 
Impact of setting  
INR measurements were classified into those ‘in range’ (INR 2-4) and those ‘out of range’ 
(<2 and >4). (Table 2) No significant difference was observed in the rate of disagreement in 
INR classification between the Stride and CoaguChek systems used within the primary care 
setting compared with the secondary care setting (10.8% versus 12.3%, difference =1.5% 
(95% CI -8.0% to 10.9%, p=0.78).    
 
Internal Quality Control 
The IQC results for all three methods were within the allowable limits. The one level IQC for 
the CoaguChek took less time to prepare than the two level IQC for the Xprecia Stride (the 
reconstituted control solution for the CoaguChek being ready for use one minute after the 
addition of the diluent versus five minutes for the Stride). Time to perform one IQC test on 
either system was similar (CoaguChek; one level IQC; 4-5 minutes versus Stride, two level 
IQC, 8-10 minutes).  
 
Technical difficulties  
No mechanical problems were encountered with the POC devices during the evaluation. 
Error messages due to application of an inadequate capillary sample were observed on the 
POC systems on 8 of 208 (3.8%) occasions. The Stride displayed this error message on 4 of 
the 8 (50%) occasions and the CoaguChek displayed this error message on 4 of the 8 
occasions (associated error rate for each system 1.9%).  
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Discussion  
In the present study the performance of the Xprecia Stride system used within both a 
primary and secondary care setting by intended users was compared with a laboratory 
method and two CoaguChek POC systems for INR estimation. Linear regression revealed 
strong correlation between the Stride and the laboratory (r=0.83) and between the Stride and 
the CoaguChek systems (r=0.92). It is recognised that this correlation only measures the 
straight line of linear association between the two measurements and does not provide a 
meaningful measure of agreement. Bland-Altman was therefore used to investigate the 
mean differences in INR between the Stride, laboratory and CoaguChek testing systems.  
Bland-Altman plots revealed good agreement within the therapeutic range between 1.5 and 
4.0, with the Stride performing on average 0.03 INR units lower than the laboratory and 0.09 
INR units lower than the CoaguChek. Although perfect agreement between the systems was 
not observed within the INR range 1.5 to 4.0, the overall variance in INR results was within 
acceptable limits with an analytical bias of more than 0.5 INR units being evident in fewer 
than 13% of samples. The overall agreement between the systems was therefore good with 
87% (75/86) of the INR results from the Stride being within 0.5 INR units of the results 
obtained by the laboratory. Furthermore, despite the use of different batches of strips, 
CoaguChek systems and other user dependant variables within and between the 
anticoagulation clinics, 93% (171/183) of the Stride and CoaguChek INRs were within 0.5 
INR units of each other. These results compare favourably with figures of 76%, 83%, 85% 
and 88% reported in previous studies comparing POC determined INR with laboratory 
determined INR. [16-19] 
Findings suggest that the Stride system has a tendency to slightly overestimate the INR 
when measurements are above the therapeutic range (>4.0) and underestimate the INR 
when the INR is within or below the therapeutic range. Similar findings however are well 
documented in other studies comparing INRs determined using POC systems with 
laboratory methods. [20-22] As such the performance of any POC system for INR estimation 
above the therapeutic range when compared with another system has to be viewed in the 
context of the inherent inaccuracies of INR measurements. Furthermore this finding is 
unlikely to be of clinical importance as management of high INRs should be clinically guided. 
[23] The accuracy of the Stride in this respect is acceptable for use in everyday clinical 
practice. Use of the two level IQC is however recommended to assess day-to-day 
consistency and ensure proper functioning of the system and test strips.  
Whilst no technical difficulties were reported during the evaluation, error messages indicating 
failed measurements were observed on both the Stride and CoaguChek systems leading to 
repeat testing. The overall rate of failed tests due to application of an inadequate sample 
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observed during the evaluation was however <4% and likely due to the per protocol 
requirement for parallel testing with application of one drop of capillary blood from one finger 
stick to two POC systems. As such these errors are less likely to occur when using the 
Stride in routine clinical practice where only one drop of capillary blood is required for INR 
estimation. The frequency and associated cost of repeat testing in routine clinical practice is 
likely therefore to be minimal.  
This evaluation has a number of strengths. The study was performed under real–life 
conditions by intended users in a primary and secondary care setting and included 
comparison of INR results with an established hospital laboratory method. Furthermore, the 
analysis employed linear regression to examine the relationship between the INR results 
obtained via the different systems and Bland-Altman plots to assess the mean differences in 
INR and agreement over the therapeutic range.  
A high number of parallel measurements (n=183) within the INR range 1.5 to 4.0 were 
undertaken on the Stride and CoaguChek, providing a precise estimation of accuracy. The 
estimation of accuracy of the Stride within the INR range 1.5 to 4.0 compared with the 
laboratory is however limited by a smaller number of samples (n=86) and as indicated by the 
wider confidence intervals around the estimates, is less precise.  
Test strip batch to batch variation comparison was not within the scope of the current study. 
As such the findings of this evaluation are limited by the use of one of batch of test strips. 
Furthermore patients with conditions known to interfere with POC INR estimation such as 
antiphospholipid syndrome, anaemia and polycythaemia were not excluded from the 
evaluation. It is possible that samples from these patient groups were included and are 
responsible for the analytical bias of more than 1.4 INR units (i.e. above the upper limit of 
agreement) evident in the comparison of the Stride and laboratory determined INRs before 
the removal of the outlying INR results.    
 
Conclusion  
INRs tested using the Xprecia Stride system showed good agreement with the laboratory 
and CoaguChek systems for patients with INR results within the therapeutic range up to an 
INR 4.0. Findings suggest that the Xprecia Stride system is accurate, reliable and 
acceptable for INR estimation in everyday clinical practice in a primary and secondary care 
setting as long as correct procedures are followed. 
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Take home messages 
• The Xprecia Stride system is a new to market, point of care (POC) coagulometer 
intended for use by healthcare professionals. 
• The British Committee for Standards in Haematology (BCSH) guidelines for POC 
testing recommend an evaluation under the conditions most likely to be encountered in 
normal everyday practice. 
• Within both a primary and secondary care setting, the overall agreement between the 
INRs determined by the Xprecia Stride, CoaguChek systems and the laboratory 
method was within acceptable limits.  
• In the hands of the intended users the Xprecia Stride is appropriate for use in 
everyday clinical practice.  
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Table 1 Description of the Xprecia Stride system 
Feature  
Specimen collection Test strip 
Quantity of blood 6µl 
Detection principle Electrochemical detection of thrombin activity 
Measurement time <1.6 minutes ( depending upon INR level) 
Measurement range 0.8-8.0 
Haematocrit 25%-50% 
Type of blood Capillary blood 
Thromboplastin Human recombinant, Dade® Innovin® 
Electrical power supply Disposable alkaline batteries/ Rechargeable nickel batteries 
Memory store 640 test results, 300 Liquid Controls and 300 error messages 
IQC Control kit comprising 2 levels of IQC supplied by manufacturer 
EQA programmes Currently WEQAS. UKNEQAS will introduce an EQA programme 
1/04/17 
Calibration Batch specific barcode on strip vial 
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Table 2. Comparison of INR measurements 
Primary care setting  
 Coaguchek    
Xprecia Stride <2 2-4  >4 Total 
<2 11 8 0 19 
2-4 0 60 1 61 
>4 0 0 3 3 
Total 11 68 4 83 
     
Secondary care setting    
 Coaguchek  
Xprecia Stride <2 2-4  >4 Total 
<2 19 9 0 28 
2-4 1 73 3 77 
>4 0 2 15 17 
Total 20 84 18 122 
   
  Laboratory  
Xprecia Stride <2 2-4  >4 Total 
<2 11 7 0 18 
2-4 0 66 2 68 
>4 0 3 13 16 
Total 11 76 15 102 
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Figure 1 Scatterplot of INR measured by Xprecia Stride versus Laboratory in a  
secondary care setting (including outliers).  
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Figure 2. Bland-Altman plot of difference in INR (Xprecia Stride minus Laboratory measurement) 
against the mean of the two measurements (including outliers).  
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Figure 3. Scatterplot of INR measured by Xprecia Stride versus CoaguChek in primary and secondary 
care settings (including outliers).  
 
 
 
20 | P a g e  
 
 
 
Figure 4. Bland-Altman plot of the difference in INR (Xprecia Stride minus Coaguchek measurement) 
against the mean of the two measurements (including outliers).   
 
 
 
 
 
 
 
 
 
